A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2016
At a glance
- Drugs Vorinostat (Primary)
- Indications Adenocarcinoma
- Focus Therapeutic Use
- 09 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 13 Nov 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Dec 2015.
- 07 Apr 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.